Parkinsonism

From Wikipedia, the free encyclopedia
  (Redirected from Secondary parkinsonism)
Jump to: navigation, search
Parkinsonism
Specialty neurology

Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural instability.[1][2] Parkinsonism is found in Parkinson's disease (after which it is named), however a wide range of other causes may lead to this set of symptoms, including some toxins, a few metabolic diseases, and a handful of neurological conditions other than Parkinson's disease.[3]

About 7% of people with parkinsonism have developed their symptoms following treatment with particular medications. Side effect of medications, mainly neuroleptic antipsychotics especially the phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupenthixol and zuclopenthixol) and butyrophenones (such as haloperidol), piperazines (such as ziprasidone), and rarely, antidepressants. The incidence of drug-induced parkinsonism increases with age. Drug-induced parkinsonism tends to remain at its presenting level, not progress like Parkinson's disease.[4]

Differential diagnoses[edit]

Differentiating some kinds of atypical Parkinson: Northwest Parkinson Foundation

Before Parkinson's disease is diagnosed, the differential diagnoses include:

References[edit]

  1. ^ a b c d e f Aminoff MJ, Greenberg DA, Simon RP (2005). Clinical Neurology (6th ed.). Lange: McGraw-Hill Medical. pp. 241–5. ISBN 0-07-142360-5. 
  2. ^ Bradley J. Robottom; William J. Weiner; Lisa M. Shulman. "42". International Neurology: A Clinical Approach. Blackwell Publishing Ltd. pp. 152–158. ISBN 978-1-405-15738-4. 
  3. ^ Christine CW, Aminoff MJ (2004). "Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance". Am. J. Med. 117 (6): 412–9. doi:10.1016/j.amjmed.2004.03.032. PMID 15380498. 
  4. ^ "Archived copy" (PDF). Archived from the original (PDF) on 2013-06-26. Retrieved 2013-04-15. 
  5. ^ Tse W, Cersosimo MG, Gracies JM, et al. (2004). "Movement disorders and AIDS: a review". Parkinsonism Relat. Disord. 10 (6): 323–34. doi:10.1016/j.parkreldis.2004.03.001. PMID 15261874. 
  6. ^ Maltête D, Guyant-Maréchal L, Mihout B, Hannequin D (2006). "Movement disorders and Creutzfeldt–Jakob disease: a review". Parkinsonism Relat. Disord. 12 (2): 65–71. doi:10.1016/j.parkreldis.2005.10.004. PMID 16364674. 
  7. ^ Dixit, Siddharth; Khan, Shahbaj A; Azad, Sudip (February 2015). "A Case of SSRI Induced Irreversible Parkinsonism". Journal of Clinical and Diagnostic Research : JCDR. 9 (2): VD01–VD02. doi:10.7860/JCDR/2015/11394.5583. ISSN 2249-782X. PMC 4378786Freely accessible. PMID 25859504. 
  8. ^ Dixit, Siddharth; Khan, Shahbaj A; Azad, Sudip (February 2015). "A Case of SSRI Induced Irreversible Parkinsonism". Journal of Clinical and Diagnostic Research : JCDR. 9 (2): VD01–VD02. doi:10.7860/JCDR/2015/11394.5583. ISSN 2249-782X. PMC 4378786Freely accessible. PMID 25859504. 
  9. ^ Watanabe Y, Himeda T, Araki T (2005). "Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease" (PDF). Med. Sci. Monit. 11 (1): RA17–23. PMID 15614202. 
  10. ^ September 2, 2009 at 5:32 AM (2009-09-02). "LINGO1 variant responsible for essential tremors and Parkinson's disease". News-medical.net. Retrieved 2017-02-24. 
  11. ^ Fabrizi, Monaco, Dalla Libera (2004). "Parkinsonian syndrome following MDMA (Ecstasy) addiction". Movement Disorders. 19: S73–S74. 
  12. ^ Wenning GK, Geser F (2003). "Multiple system atrophy". Rev. Neurol. (Paris). 159 (5 Pt 2): 3S31–8. PMID 12773886. 
  13. ^ Uc EY, Rodnitzky RL (2003). "Childhood dystonia". Seminars in pediatric neurology. 10 (1): 52–61. doi:10.1016/S1071-9091(02)00010-4. PMID 12785748. 
  14. ^ Online Mendelian Inheritance in Man (OMIM) NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1 -234200
  15. ^ a b c DeLong MR, Juncos JL (2004). Parkinson's Disease and Other Movement Disorders. In: Harrison's Principles of Internal Medicine (16th ed.). McGraw-Hill Professional. p. 2414. ISBN 0-07-140235-7. 
  16. ^ Dinis-Oliveira RJ, Remião F, Carmo H, et al. (2006). "Paraquat exposure as an etiological factor of Parkinson's disease". Neurotoxicology. 27 (6): 1110–22. doi:10.1016/j.neuro.2006.05.012. PMID 16815551. 
  17. ^ Tremor/InvoluntaryMovements: Excerpt from Field Guide to Bedside Diagnosis Archived 2010-02-03 at the Wayback Machine.
  18. ^ Weiss J. Chapter 151. Toluene and Xylene. In: Olson KR, ed. Poisoning & Drug Overdose. 6th ed. New York: McGraw-Hill; 2012. http://www.accessmedicine.com/content.aspx?aID=55982958. Accessed April 21, 2013.
  19. ^ Uitti, Ryan J.; Snow, Barry J.; Shinotoh, Hitoshi; Vingerhoets, Francois J. G.; Hayward, Margo; Hashimoto, Stanley; Richmond, John; Markey, Sanford P.; Markey, Carol J.; Calne, Donald B. (1994). "Parkinsonism induced by solvent abuse". Annals of Neurology. 35 (5): 616. doi:10.1002/ana.410350516. PMID 8179306. 
  20. ^ Thanvi B, Lo N, Robinson T (2005). "Vascular Parkinsonism--an important cause of parkinsonism in older people" (PDF). Age and ageing. 34 (2): 114–9. doi:10.1093/ageing/afi025. PMID 15713855. 
  21. ^ "Parkinson's Insights: Vascular parkinsonism". Parkinsonsdiseasefoundation.blogspot.com. 2012-08-07. Retrieved 2017-02-24. 
  22. ^ Członkowska A, Tarnacka B, Möller JC, et al. (2007). "Unified Wilson's Disease Rating Scale — a proposal for the neurological scoring of Wilson's disease patients". Neurol. Neurochir. Pol. 41 (1): 1–12. PMID 17330175. 
  23. ^ Ropper AH, Samuels MA. Chapter 4. Abnormalities of Movement and Posture Caused by Disease of the Basal Ganglia. In: Ropper AH, Samuels MA, eds. Adams and Victor's Principles of Neurology. 9th ed. New York: McGraw-Hill; 2009. http://www.accessmedicine.com/content.aspx?aID=3630437. Accessed April 21, 2013.
  24. ^ Lorincz MT (January 2010). "Neurologic Wilson's disease". Ann. N. Y. Acad. Sci. 1184: 173–87. Bibcode:2010NYASA1184..173L. doi:10.1111/j.1749-6632.2009.05109.x. PMID 20146697. 

External links[edit]

Classification
V · T · D
External resources